MicroRNA-22 acts as a metastasis suppressor by targeting metadherin in gastric cancer

Molecular Medicine Reports

Volumn 11, Issue 1, 2015, Pages 454-460

  Tang, Yunyun ^a   Liu, Xiaoping ^b   Su, Bo ^a   Zhang, Zhiwei ^a   Zeng, Xi ^a   Lei, Yanping ^a   Shan, Jian ^a   Wu, Yongjun ^a   Tang, Hailin ^b   Su, Qi ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Gastric cancer; Metadherin; Metastasis; MicroRNA 22

Indexed keywords

METADHERIN; MICRORNA 22; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; MESSENGER RNA; MICRORNA; MIRN22 MICRORNA, HUMAN; MTDH PROTEIN, HUMAN; ANTIMETASTATIC AGENT; LUCIFERASE; PROTEIN;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER STAGING; CELL INVASION; CELL INVASION ASSAY; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; MOLECULAR MECHANICS; PROTEIN EXPRESSION; PROTEIN FUNCTION; STOMACH CANCER; TUMOR XENOGRAFT; ANIMAL; CELL MOTION; DISEASE MODEL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; RNA INTERFERENCE; STOMACH TUMOR; TUMOR CELL LINE; XENOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELL MIGRATION ASSAY; DRUG MECHANISM; ECTOPIC EXPRESSION; GASTRIC CANCER CELL LINE; METASTASIS INHIBITION; MOUSE; NONHUMAN; TUMOR INVASION;

ANIMALS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; LYMPHATIC METASTASIS; MICRORNAS; NEOPLASM METASTASIS; NEOPLASM STAGING; RNA INTERFERENCE; RNA, MESSENGER; STOMACH NEOPLASMS;

EID: 84916200505     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2682     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Coburn NG: Lymph nodes and gastric cancer. J Surg Oncol 99: 199-206, 2009.
3. Tang H, Liu X, Wang Z, et al: Interaction of hsa-miR-381 and glioma suppressor LRRC4 is involved in glioma growth. Brain Res 1390: 21-32, 2011.
4. Cheng CJ and Slack FJ: The duality of oncomiR addiction in the maintenance and treatment of cancer. Cancer J 18: 232-237, 2012.
5. Tang H, Deng M, Tang Y, et al: miR-200b and miR-200c as prognostic factors and mediators of gastric cancer cell progression. Clin Cancer Res 19: 5602-5612, 2013.
6. Zheng B, Liang L, Wang C, et al: MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res 17: 7574-7583, 2011.
7. Liu D, Xia P, Diao D, et al: MiRNA-429 suppresses the growth of gastric cancer cells in vitro. J Biomed Res 26: 389-393, 2012.
8. He XP, Shao Y, Li XL, et al: Downregulation of miR-101 in gastric cancer correlates with cyclooxygenase-2 overexpression and tumor growth. FEBS J 279: 4201-4212, 2012.
9. Zhang L, Liu X, Jin H, et al: miR-206 inhibits gastric cancer proliferation in part by repressing cyclinD2. Cancer Lett 332: 94-101, 2013.
10. Qin S, Ai F, Ji WF, Rao W, Zhang HC and Yao WJ: miR-19a promotes cell growth and tumorigenesis through targeting SOCS1 in gastric cancer. Asian Pac J Cancer Prev 14: 835-840, 2013.
11. Wang M, Li C, Yu B, et al: Overexpressed miR-301a promotes cell proliferation and invasion by targeting RUNX3 in gastric cancer. J Gastroenterol 48: 1023-1033, 2013.
12. Wu W, Takanashi M, Borjigin N, et al: MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis. Br J Cancer 108: 653-661, 2013.
13. Yang ZX, Lu CY, Yang YL, Dou KF and Tao KS: MicroRNA-125b expression in gastric adenocarcinoma and its effect on the proliferation of gastric cancer cells. Mol Med Rep 7: 229-232, 2013.
14. Zhi Q, Guo X, Guo L, et al: Oncogenic miR-544 is an important molecular target in gastric cancer. Anticancer Agents Med Chem 13: 270-275, 2013.
15. Guo JX, Tao QS, Lou PR, Chen XC, Chen J and Yuan GB: miR-181b as a potential molecular target for anticancer therapy of gastric neoplasms. Asian Pac J Cancer Prev 13: 2263-2267, 2012.
16. Tang H, Kong Y, Guo J, et al: Diallyl disulfde suppresses proliferation and induces apoptosis in human gastric cancer through Wnt-1 signaling pathway by up-regulation of miR-200b and miR-22. Cancer Lett 340: 72-81, 2013.
17. Guo MM, Hu LH, Wang YQ, et al: miR-22 is down-regulated in gastric cancer, and its overexpression inhibits cell migration and invasion via targeting transcription factor Sp1. Med Oncol 30: 542, 2013.
18. Li B, Song Y, Liu TJ, et al: miRNA-22 suppresses colon cancer cell migration and invasion by inhibiting the expression of T-cell lymphoma invasion and metastasis 1 and matrix metallopro-teinases 2 and 9. Oncol Rep 29: 1932-1938, 2013.
19. Ling B, Wang GX, Long G, Qiu JH and Hu ZL: Tumor suppressor miR-22 suppresses lung cancer cell progression through post-transcriptional regulation of ErbB3. J Cancer Res Clin Oncol 138: 1355-1361, 2012.
20. Xiong J, Yu D, Wei N, et al: An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples. FEBS J 277: 1684-1694, 2010.
21. Wang W, Li F, Zhang Y, Tu Y, Yang Q and Gao X: Reduced expression of miR-22 in gastric cancer is related to clinicopathologic characteristics or patient prognosis. Diagn Pathol 8: 102, 2013.
22. Song SJ, Ito K, Ala U, et al: The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell 13: 87-101, 2013.
23. Kang DC, Su ZZ, Sarkar D, Emdad L, Volsky DJ and Fisher PB: Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1. Gene 353: 8-15, 2005.
24. Liu L, Wu J, Ying Z, et al: Astrocyte elevated gene-1 upregulates matrix metalloproteinase-9 and induces human glioma invasion. Cancer Res 70: 3750-3759, 2010.
25. Ahn S, Hyeon J and Park CK: Metadherin is a prognostic predictor of hepatocellular carcinoma after curative hepatectomy. Gut Liver 7: 206-212, 2013.
26. Wang N, Du X, Zang L, et al: Prognostic impact of Metadherin-SND1 interaction in colon cancer. Mol Biol Rep 39: 10497-10504, 2012.
27. Tokunaga E, Nakashima Y, Yamashita N, et al: Overexpression of metadherin/MTDH is associated with an aggressive phenotype and a poor prognosis in invasive breast cancer. Breast Cancer 21: 341-349, 2014.
28. Zhou J, Li J, Wang Z, Yin C and Zhang W: Metadherin is a novel prognostic marker for bladder cancer progression and overall patient survival. Asia Pac J Clin Oncol 8: e42-e48, 2012.
29. Meng X, Brachova P, Yang S, et al: Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment. PLoS One 6: e20920, 2011.
30. Ge X, Lv X, Feng L, et al: Metadherin contributes to the pathogenesis of diffuse large B-cell lymphoma. PLoS One 7: e39449, 2012.
31. Zhang J, Zhang Y, Liu S, et al: Metadherin confers chemoresistance of cervical cancer cells by inducing autophagy and activating ERK/NF-κB pathway. Tumour Biol 34: 2433-2440, 2013.
32. Hu G, Wei Y and Kang Y: The multifaceted role of MTDH/A E G-1 in cancer progression. Clin Cancer Res 15: 5615-5620, 2009.
33. Li X, Kong X, Huo Q, et al: Metadherin enhances the invasiveness of breast cancer cells by inducing epithelial to mesenchymal transition. Cancer Sci 102: 1151-1157, 2011.
34. Zhu K, Dai Z, Pan Q, et al: Metadherin promotes hepatocellular carcinoma metastasis through induction of epithelial-mesen-chymal transition. Clin Cancer Res 17: 7294-7302, 2011.